The study drug (STK-002) is designed to help the body make more of a certain protein, OPA1, which is needed for vision. Because of your ADOA, you may have less OPA1 protein than people without ADOA. Making more of this protein may help stop or slow the vision loss caused by ADOA. The study drug is investigational, which means it can only be used in research studies. It has not been approved by any health authority as a therapy for ADOA.
Participants of the study will receive a one-time injection of the study drug (STK-002) in one eye on Day 1. After you receive the study drug, you will stay at the study clinic for several hours, so the study staff can monitor your health.
If you'd like to learn more about the injection process and experience, please watch this short, animated video.
Investigational means the Study Drug is not approved by regulatory authorities like the Medicines and Healthcare products Regulatory Agency (MHRA), and it can only be used in clinical research studies like the Osprey study.